Abbott Laboratories (NYSE:ABT) Shares Purchased by Oakworth Capital Inc.

Oakworth Capital Inc. grew its position in shares of Abbott Laboratories (NYSE:ABT) by 5.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 5,560 shares of the healthcare product maker’s stock after purchasing an additional 311 shares during the quarter. Oakworth Capital Inc.’s holdings in Abbott Laboratories were worth $612,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of ABT. TRUE Private Wealth Advisors lifted its holdings in Abbott Laboratories by 16.0% in the 4th quarter. TRUE Private Wealth Advisors now owns 6,010 shares of the healthcare product maker’s stock valued at $662,000 after acquiring an additional 830 shares during the last quarter. Scissortail Wealth Management LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at $1,778,000. Tyche Wealth Partners LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter worth $1,328,000. Allen Capital Group LLC boosted its position in shares of Abbott Laboratories by 16.5% in the 4th quarter. Allen Capital Group LLC now owns 3,969 shares of the healthcare product maker’s stock valued at $437,000 after purchasing an additional 562 shares during the period. Finally, Eagle Bluffs Wealth Management LLC increased its position in shares of Abbott Laboratories by 0.9% in the fourth quarter. Eagle Bluffs Wealth Management LLC now owns 13,216 shares of the healthcare product maker’s stock worth $1,455,000 after acquiring an additional 124 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 12,500 shares of Abbott Laboratories stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the executive vice president now directly owns 78,704 shares of the company’s stock, valued at $9,444,480. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the executive vice president now owns 78,704 shares of the company’s stock, valued at $9,444,480. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP John A. Jr. Mccoy sold 472 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the completion of the transaction, the vice president now directly owns 18,760 shares in the company, valued at $2,223,060. The disclosure for this sale can be found here. Insiders have sold 56,435 shares of company stock worth $6,451,298 over the last three months. Company insiders own 0.47% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of NYSE ABT traded down $3.30 during trading hours on Wednesday, reaching $105.91. The stock had a trading volume of 9,368,930 shares, compared to its average volume of 5,637,811. The company has a market cap of $183.77 billion, a price-to-earnings ratio of 33.50, a PEG ratio of 2.62 and a beta of 0.74. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16. The business’s fifty day moving average is $114.57 and its two-hundred day moving average is $107.60. Abbott Laboratories has a twelve month low of $89.67 and a twelve month high of $121.64.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.19. The firm had revenue of $10.24 billion during the quarter, compared to analyst estimates of $10.19 billion. Abbott Laboratories had a net margin of 14.27% and a return on equity of 20.65%. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.03 earnings per share. As a group, research analysts expect that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 2.08%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s dividend payout ratio is 67.48%.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of research reports. Royal Bank of Canada reissued an “outperform” rating and set a $128.00 price objective on shares of Abbott Laboratories in a research report on Wednesday, February 14th. Citigroup increased their price objective on Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Evercore ISI lifted their target price on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Barclays raised their price target on shares of Abbott Laboratories from $133.00 to $141.00 and gave the company an “overweight” rating in a report on Friday, January 26th. Finally, TheStreet upgraded Abbott Laboratories from a “c+” rating to a “b-” rating in a report on Thursday, December 21st. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $122.14.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.